What constitutes a drug as misbranded?

A drug is considered misbranded when its label is false or misleading. This designation includes situations where the labeling fails to provide accurate information regarding the drug's identity, composition, or intended use. Misleading information can pose significant risks to patients and consumers, who rely on accurate labeling to make informed decisions about their health and medication.

For example, if a drug’s label suggests it can cure certain conditions without scientific backing or misrepresents the contents of the medication, it can lead to misuse or adverse health effects. Misbranding is a crucial aspect of regulatory standards as it ensures that consumers receive truthful and clear information about the products they use, thereby protecting public health.

In contrast, a label that is informative and clear does not constitute misbranding, and the absence of clear pricing or branding under a premium name alone does not necessarily imply that the product is misbranded.